Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Molecular Pharmacology
  4. Volume 17, Issue 1
  5. Article
Volume 17, Issue 1
  • ISSN: 1874-4672
  • E-ISSN: 1874-4702
file format pdf download PDF
side by side viewer icon HTML

Abstract

Globally, there remains an unwavering increase in the incidence of cvd - from 271 million in 1990 to 523 million in 2019. Among the several modifiable and non-modifiable risk factors of heart disease, dyslipidemia is an important and prevalent risk factor mediated by both genetics and lifestyle factors. Hence, lowering lipid levels, specifically, ldl-c levels (low-density lipoprotein cholesterol), is a key strategy in decreasing the risk of cardiovascular disease. A reduction of 20 mg/dl in ldl-c levels has been found to prevent 2-3 cases of coronary artery disease (cad) for every 1000 individuals. Studies have also found reductions in ldl-c levels to be associated with a mortality benefit. However, ldl-c levels reduction may not eliminate the risk of significant cardiovascular events.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cmp/10.2174/0118761429264553231204115314
2024-01-01
2025-01-22

  • From This Site

    /content/journals/cmp/10.2174/0118761429264553231204115314
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cmp/17/1/BMS-CMP-2023-139.html?itemId=/content/journals/cmp/10.2174/0118761429264553231204115314&mimeType=html&fmt=ahah

References

  1. TsaoC.W. AdayA.W. AlmarzooqZ.I. AndersonC.A.M. AroraP. AveryC.L. Baker-SmithC.M. BeatonA.Z. BoehmeA.K. BuxtonA.E. Commodore-MensahY. ElkindM.S.V. EvensonK.R. Eze-NliamC. FugarS. GenerosoG. HeardD.G. HiremathS. HoJ.E. KalaniR. KaziD.S. KoD. LevineD.A. LiuJ. MaJ. MagnaniJ.W. MichosE.D. MussolinoM.E. NavaneethanS.D. ParikhN.I. PoudelR. Rezk-HannaM. RothG.A. ShahN.S. St-OngeM.P. ThackerE.L. ViraniS.S. VoeksJ.H. WangN.Y. WongN.D. WongS.S. YaffeK. MartinS.S. Heart disease and stroke statistics—2023 update: A report from the American heart association.Circulation20231478e93e62110.1161/CIR.000000000000112336695182
     [Google Scholar]
  2. RothG.A. MensahG.A. JohnsonC.O. AddoloratoG. AmmiratiE. BaddourL.M. BarengoN.C. BeatonA.Z. BenjaminE.J. BenzigerC.P. BonnyA. BrauerM. BrodmannM. CahillT.J. CarapetisJ. CatapanoA.L. ChughS.S. CooperL.T. CoreshJ. CriquiM. DeCleeneN. EagleK.A. Emmons-BellS. FeiginV.L. Fernández-SolàJ. FowkesG. GakidouE. GrundyS.M. HeF.J. HowardG. HuF. InkerL. KarthikeyanG. KassebaumN. KoroshetzW. LavieC. Lloyd-JonesD. LuH.S. MirijelloA. TemesgenA.M. MokdadA. MoranA.E. MuntnerP. NarulaJ. NealB. NtsekheM. Moraes de OliveiraG. OttoC. OwolabiM. PrattM. RajagopalanS. ReitsmaM. RibeiroA.L.P. RigottiN. RodgersA. SableC. ShakilS. Sliwa-HahnleK. StarkB. SundströmJ. TimpelP. TleyjehI.M. ValgimigliM. VosT. WheltonP.K. YacoubM. ZuhlkeL. MurrayC. FusterV. RothG.A. MensahG.A. JohnsonC.O. AddoloratoG. AmmiratiE. BaddourL.M. BarengoN.C. BeatonA. BenjaminE.J. BenzigerC.P. BonnyA. BrauerM. BrodmannM. CahillT.J. CarapetisJ.R. CatapanoA.L. ChughS. CooperL.T. CoreshJ. CriquiM.H. DeCleeneN.K. EagleK.A. Emmons-BellS. FeiginV.L. Fernández-SolaJ. FowkesF.G.R. GakidouE. GrundyS.M. HeF.J. HowardG. HuF. InkerL. KarthikeyanG. KassebaumN.J. KoroshetzW.J. LavieC. Lloyd-JonesD. LuH.S. MirijelloA. MisganawA.T. MokdadA.H. MoranA.E. MuntnerP. NarulaJ. NealB. NtsekheM. OliveiraG.M.M. OttoC.M. OwolabiM.O. PrattM. RajagopalanS. ReitsmaM.B. RibeiroA.L.P. RigottiN.A. RodgersA. SableC.A. ShakilS.S. SliwaK. StarkB.A. SundströmJ. TimpelP. TleyjehI.I. ValgimigliM. VosT. WheltonP.K. YacoubM. ZuhlkeL.J. Abbasi-KangevariM. AbdiA. AbediA. AboyansV. AbrhaW.A. Abu-GharbiehE. AbushoukA.I. AcharyaD. AdairT. AdebayoO.M. AdemiZ. AdvaniS.M. AfshariK. AfshinA. AgarwalG. AgasthiP. AhmadS. AhmadiS. AhmedM.B. AjiB. AkaluY. Akande-SholabiW. AkliluA. AkunnaC.J. AlahdabF. Al-EyadhyA. AlhabibK.F. AlifS.M. AlipourV. AljunidS.M. AllaF. Almasi-HashianiA. AlmustanyirS. Al-RaddadiR.M. AmegahA.K. AminiS. AminorroayaA. AmuH. AmugsiD.A. AncuceanuR. AnderliniD. AndreiT. AndreiC.L. Ansari-MoghaddamA. AntenehZ.A. AntonazzoI.C. AntonyB. AnwerR. AppiahL.T. ArablooJ. ÄrnlövJ. ArtantiK.D. AtaroZ. AusloosM. Avila-BurgosL. AwanA.T. AwokeM.A. AyeleH.T. AyzaM.A. AzariS. BD.B. BaheiraeiN. BaigA.A. BakhtiariA. BanachM. BanikP.C. BaptistaE.A. BarbozaM.A. BaruaL. BasuS. BediN. BéjotY. BennettD.A. BensenorI.M. BermanA.E. BezabihY.M. BhagavathulaA.S. BhaskarS. BhattacharyyaK. BijaniA. BikbovB. BirhanuM.M. BoloorA. BrantL.C. BrennerH. BrikoN.I. ButtZ.A. Caetano dos SantosF.L. CahillL.E. Cahuana-HurtadoL. CámeraL.A. Campos-NonatoI.R. Cantu-BritoC. CarJ. CarreroJ.J. CarvalhoF. Castañeda-OrjuelaC.A. Catalá-LópezF. CerinE. CharanJ. ChattuV.K. ChenS. ChinK.L. ChoiJ-Y.J. ChuD-T. ChungS-C. CirilloM. CoffeyS. ContiS. CostaV.M. CundiffD.K. DadrasO. DagnewB. DaiX. DamascenoA.A.M. DandonaL. DandonaR. DavletovK. De la Cruz-GóngoraV. De la HozF.P. De NeveJ-W. Denova-GutiérrezE. Derbew MollaM. DersehB.T. DesaiR. DeuschlG. DharmaratneS.D. DhimalM. DhunganaR.R. DianatinasabM. DiazD. DjalaliniaS. DokovaK. DouiriA. DuncanB.B. DuraesA.R. EaganA.W. EbtehajS. EftekhariA. EftekharzadehS. EkholuenetaleM. El NahasN. ElgendyI.Y. ElhadiM. El-JaafaryS.I. EsteghamatiS. EtissoA.E. EyawoO. FadhilI. FaraonE.J.A. FarisP.S. FarwatiM. FarzadfarF. FernandesE. Fernandez PrendesC. FerraraP. FilipI. FischerF. FloodD. FukumotoT. GadM.M. GaidhaneS. GanjiM. GargJ. GebreA.K. GebregiorgisB.G. GebregzabiherK.Z. GebremeskelG.G. GetacherL. ObsaA.G. GhajarA. GhashghaeeA. GhithN. GiampaoliS. GilaniS.A. GillP.S. GillumR.F. GlushkovaE.V. GnedovskayaE.V. GolechhaM. GonfaK.B. GoudarzianA.H. GoulartA.C. GuadamuzJ.S. GuhaA. GuoY. GuptaR. HachinskiV. Hafezi-NejadN. HaileT.G. HamadehR.R. HamidiS. HankeyG.J. HargonoA. HartonoR.K. HashemianM. HashiA. HassanS. HassenH.Y. HavmoellerR.J. HayS.I. HayatK. HeidariG. HerteliuC. HollaR. HosseiniM. HosseinzadehM. HostiucM. HostiucS. HousehM. HuangJ. HumayunA. IavicoliI. IbenemeC.U. IbitoyeS.E. IlesanmiO.S. IlicI.M. IlicM.D. IqbalU. IrvaniS.S.N. IslamS.M.S. IslamR.M. IsoH. IwagamiM. JainV. JavaheriT. JayapalS.K. JayaramS. JayawardenaR. JeemonP. JhaR.P. JonasJ.B. JonnagaddalaJ. JoukarF. JozwiakJ.J. JürissonM. KabirA. KahlonT. KalaniR. KalhorR. KamathA. KamelI. KandelH. KandelA. KarchA. KasaA.S. KatotoP.D.M.C. KayodeG.A. KhaderY.S. KhammarniaM. KhanM.S. KhanM.N. KhanM. KhanE.A. KhatabK. KibriaG.M.A. KimY.J. KimG.R. KimokotiR.W. KisaS. KisaA. KivimäkiM. KolteD. KoolivandA. KorshunovV.A. Koulmane LaxminarayanaS.L. KoyanagiA. KrishanK. KrishnamoorthyV. Kuate DefoB. Kucuk BicerB. KulkarniV. KumarG.A. KumarN. KurmiO.P. KusumaD. KwanG.F. La VecchiaC. LaceyB. LallukkaT. LanQ. LasradoS. LassiZ.S. LauriolaP. LawrenceW.R. LaxmaiahA. LeGrandK.E. LiM-C. LiB. LiS. LimS.S. LimL-L. LinH. LinZ. LinR-T. LiuX. LopezA.D. LorkowskiS. LotufoP.A. LugoA. MN.K. MadottoF. MahmoudiM. MajeedA. MalekzadehR. MalikA.A. MamunA.A. ManafiN. MansourniaM.A. MantovaniL.G. MartiniS. MathurM.R. MazzagliaG. MehataS. MehndirattaM.M. MeierT. MenezesR.G. MeretojaA. MestrovicT. MiazgowskiB. MiazgowskiT. MichalekI.M. MillerT.R. MirrakhimovE.M. MirzaeiH. MoazenB. MoghadaszadehM. MohammadY. MohammadD.K. MohammedS. MohammedM.A. MokhayeriY. MolokhiaM. MontasirA.A. MoradiG. MoradzadehR. MoragaP. MorawskaL. Moreno VelásquezI. MorzeJ. MubarikS. MuruetW. MusaK.I. NagarajanA.J. NaliniM. NangiaV. NaqviA.A. Narasimha SwamyS. NascimentoB.R. NayakV.C. NazariJ. NazarzadehM. NegoiR.I. Neupane KandelS. NguyenH.L.T. NixonM.R. NorrvingB. NoubiapJ.J. NoutheB.E. NowakC. OdukoyaO.O. OgboF.A. OlagunjuA.T. OrruH. OrtizA. OstroffS.M. PadubidriJ.R. PalladinoR. PanaA. Panda-JonasS. ParekhU. ParkE-C. ParviziM. Pashazadeh KanF. PatelU.K. PathakM. PaudelR. PepitoV.C.F. PerianayagamA. PericoN. PhamH.Q. PilgrimT. PiradovM.A. PishgarF. PodderV. PolibinR.V. PourshamsA. PribadiD.R.A. RabieeN. RabieeM. RadfarA. RafieiA. RahimF. Rahimi-MovagharV. Ur RahmanM.H. RahmanM.A. RahmaniA.M. RakovacI. RamP. RamalingamS. RanaJ. RanasingheP. RaoS.J. RathiP. RawalL. RawasiaW.F. RawassizadehR. RemuzziG. RenzahoA.M.N. RezapourA. RiahiS.M. Roberts-ThomsonR.L. RoeverL. RohloffP. RomoliM. RoshandelG. RwegereraG.M. SaadatagahS. Saber-AyadM.M. SabourS. SaccoS. SadeghiM. Saeedi MoghaddamS. SafariS. SahebkarA. SalehiS. SalimzadehH. SamaeiM. SamyA.M. SantosI.S. Santric-MilicevicM.M. SarrafzadeganN. SarveazadA. SathishT. SawhneyM. SaylanM. SchmidtM.I. SchutteA.E. SenthilkumaranS. SepanlouS.G. ShaF. ShahabiS. ShahidI. ShaikhM.A. ShamaliM. ShamsizadehM. ShawonM.S.R. SheikhA. ShigematsuM. ShinM-J. ShinJ.I. ShiriR. ShiueI. ShuvalK. SiabaniS. SiddiqiT.J. SilvaD.A.S. SinghJ.A. MtechA.S. SkryabinV.Y. SkryabinaA.A. SoheiliA. SpurlockE.E. StockfeltL. StorteckyS. StrangesS. Suliankatchi AbdulkaderR. TadbiriH. TadesseE.G. TadesseD.B. TajdiniM. TariqujjamanM. TeklehaimanotB.F. TemsahM-H. TesemaA.K. ThakurB. ThankappanK.R. ThaparR. ThriftA.G. TimalsinaB. TonelliM. TouvierM. Tovani-PaloneM.R. TripathiA. TripathyJ.P. TruelsenT.C. TsegayG.M. TsegayeG.W. TsilimparisN. TusaB.S. TyrovolasS. UmapathiK.K. UnimB. UnnikrishnanB. UsmanM.S. VaduganathanM. ValdezP.R. VasankariT.J. VelazquezD.Z. VenketasubramanianN. VuG.T. VujcicI.S. WaheedY. WangY. WangF. WeiJ. WeintraubR.G. WeldemariamA.H. WestermanR. WinklerA.S. WiysongeC.S. WolfeC.D.A. WubishetB.L. XuG. YadollahpourA. YamagishiK. YanL.L. YandrapalliS. YanoY. YatsuyaH. YeheyisT.Y. YeshawY. YilgwanC.S. YonemotoN. YuC. YusefzadehH. ZachariahG. ZamanS.B. ZamanM.S. ZamanianM. ZandR. ZandifarA. ZarghiA. ZastrozhinM.S. ZastrozhinaA. ZhangZ-J. ZhangY. ZhangW. ZhongC. ZouZ. ZunigaY.M.H. MurrayC.J.L. FusterV. Global burden of cardiovascular diseases and risk factors, 1990–2019.J. Am. Coll. Cardiol.202076252982302110.1016/j.jacc.2020.11.01033309175
     [Google Scholar]
  3. YusufS. HawkenS. ÔunpuuS. DansT. AvezumA. LanasF. McQueenM. BudajA. PaisP. VarigosJ. LishengL. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.Lancet2004364943893795210.1016/S0140‑6736(04)17018‑915364185
     [Google Scholar]
  4. ArnettD.K. BlumenthalR.S. AlbertM.A. BurokerA.B. GoldbergerZ.D. HahnE.J. HimmelfarbC.D. KheraA. Lloyd-JonesD. McEvoyJ.W. MichosE.D. MiedemaM.D. MuñozD. SmithS.C.Jr ViraniS.S. WilliamsK.A.Sr YeboahJ. ZiaeianB. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease.J. Am. Coll. Cardiol.20197410e177e23210.1016/j.jacc.2019.03.01030894318
     [Google Scholar]
  5. GiuglianoR.P. KeechA. MurphyS.A. HuberK. TokgozogluS.L. LewisB.S. FerreiraJ. PinedaA.L. SomaratneR. SeverP.S. PedersenT.R. SabatineM.S. Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin.JAMA Cardiol.20172121385139110.1001/jamacardio.2017.394429117276
     [Google Scholar]
  6. SchwartzG.G. StegP.G. SzarekM. BhattD.L. BittnerV.A. DiazR. EdelbergJ.M. GoodmanS.G. HanotinC. HarringtonR.A. JukemaJ.W. LecorpsG. MahaffeyK.W. MoryusefA. PordyR. QuinteroK. RoeM.T. SasielaW.J. TambyJ.F. TricociP. WhiteH.D. ZeiherA.M. Alirocumab and cardiovascular outcomes after acute coronary syndrome.N. Engl. J. Med.2018379222097210710.1056/NEJMoa180117430403574
     [Google Scholar]
  7. NeatonJ.D. WentworthD. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men.Arch. Intern. Med.19921521566410.1001/archinte.1992.004001300820091728930
     [Google Scholar]
  8. Heart protection study collaborative g. mrc/bhf heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebocontrolled trial.Lancet2002360932672210.1016/S0140‑6736(02)09327‑312114036
     [Google Scholar]
  9. KonesR. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.Ther. Adv. Cardiovasc. Dis.20093430931510.1177/175394470933705619460829
     [Google Scholar]
  10. García RuizF.J. IbáñezA.M. Pérez-JiménezF. PintóX. NoceaG. AhumadaC. AlemaoE. YinD. Current lipid management and low cholesterol goal attainment in common daily practice in Spain.PharmacoEconomics200422S3Suppl. 311210.2165/00019053‑200422003‑0000215669149
     [Google Scholar]
  11. LawlerP.R. AkinkuolieA.O. HaradaP. GlynnR.J. ChasmanD.I. RidkerP.M. MoraS. Residual risk of atherosclerotic cardiovascular events in relation to reductions in very‐low‐density lipoproteins.J. Am. Heart Assoc.2017612e00740210.1161/JAHA.117.00740229223956
     [Google Scholar]
  12. MarcovinaS.M. ShapiroM.D. Measurement of Lipoprotein(a).J. Am. Coll. Cardiol.202279762963110.1016/j.jacc.2021.11.05335177191
     [Google Scholar]
  13. Reyes-SofferG. GinsbergH.N. BerglundL. DuellP.B. HeffronS.P. KamstrupP.R. Lloyd-JonesD.M. MarcovinaS.M. YeangC. KoschinskyM.L. Lipoprotein(a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: A scientific statement from the american heart association.Arterioscler. Thromb. Vasc. Biol.2022421e48e6010.1161/ATV.000000000000014734647487
     [Google Scholar]
  14. UtermannG. Genetic architecture and evolution of the lipoprotein(a) trait.Curr. Opin. Lipidol.199910213314210.1097/00041433‑199904000‑0000710327281
     [Google Scholar]
  15. KostnerK.M. KostnerG.M. Lipoprotein (a): a historical appraisal.J. Lipid Res.201758111410.1194/jlr.R07157127821413
     [Google Scholar]
  16. NordestgaardB.G. ChapmanM.J. RayK. BorénJ. AndreottiF. WattsG.F. GinsbergH. AmarencoP. CatapanoA. DescampsO.S. FisherE. KovanenP.T. KuivenhovenJ.A. LesnikP. MasanaL. ReinerZ. TaskinenM.R. TokgözogluL. Tybjærg-HansenA. Lipoprotein(a) as a cardiovascular risk factor: Current status.Eur. Heart J.201031232844285310.1093/eurheartj/ehq38620965889
     [Google Scholar]
  17. KamstrupP.R. BennM. Tybjærg-HansenA. NordestgaardB.G. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: The copenhagen city heart study.Circulation2008117217618410.1161/CIRCULATIONAHA.107.71569818086931
     [Google Scholar]
  18. SwerdlowD.I. RiderD.A. YavariA. Wikström LindholmM. CampionG.V. NissenS.E. Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: The emerging potential of RNA interference therapeutics.Cardiovasc. Res.202211851218123110.1093/cvr/cvab10033769464
     [Google Scholar]
  19. TsimikasS. GordtsP.L.S.M. NoraC. YeangC. WitztumJ.L. Statin therapy increases lipoprotein(a) levels.Eur. Heart J.202041242275228410.1093/eurheartj/ehz31031111151
     [Google Scholar]
  20. de BoerL.M. OorthuysA.O.J. WiegmanA. LangendamM.W. KroonJ. SpijkerR. ZwindermanA.H. HuttenB.A. Statin therapy and lipoprotein(a) levels: A systematic review and meta-analysis.Eur. J. Prev. Cardiol.202229577979210.1093/eurjpc/zwab17134849724
     [Google Scholar]
  21. ScanuA.M. BambaR. Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations.Am. J. Cardiol.20081018S44S4710.1016/j.amjcard.2008.02.03118375241
     [Google Scholar]
  22. ParishS. HopewellJ.C. HillM.R. MarcovinaS. Valdes-MarquezE. HaynesR. OfferA. PedersenT.R. BaigentC. CollinsR. LandrayM. ArmitageJ. Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) lowering in the HPS2-THRIVE study.Circ. Genom. Precis. Med.2018112e00169610.1161/CIRCGEN.117.00169629449329
     [Google Scholar]
  23. ChemelloK. ChanD.C. LambertG. WattsG.F. Recent advances in demystifying the metabolism of lipoprotein(a).Atherosclerosis2022349829110.1016/j.atherosclerosis.2022.04.00235606080
     [Google Scholar]
  24. AndersonT.J. BodenW.E. Desvigne-NickensP. FlegJ.L. KashyapM.L. McBrideR. ProbstfieldJ.L. Safety profile of extended-release niacin in the AIM-HIGH trial.N. Engl. J. Med.2014371328829010.1056/NEJMc131103925014706
     [Google Scholar]
  25. LandrayM.J. HaynesR. HopewellJ.C. ParishS. AungT. TomsonJ. WallendszusK. CraigM. JiangL. CollinsR. ArmitageJ. Effects of extended-release niacin with laropiprant in high-risk patients.N. Engl. J. Med.2014371320321210.1056/NEJMoa130095525014686
     [Google Scholar]
  26. AwadK. MikhailidisD.P. KatsikiN. MuntnerP. BanachM. Effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia: A systematic review and meta-analysis of randomized controlled trials.Drugs201878445346210.1007/s40265‑018‑0870‑129396832
     [Google Scholar]
  27. SahebkarA. Simental-MendíaL.E. PirroM. BanachM. WattsG.F. SirtoriC. Al-RasadiK. AtkinS.L. Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: A systematic review and meta-analysis of randomized controlled trials.Sci. Rep.2018811788710.1038/s41598‑018‑36204‑730552391
     [Google Scholar]
  28. FarmakisI. DoundoulakisI. PagiantzaA. ZafeiropoulosS. AntzaC. KarvounisH. GiannakoulasG. Lipoprotein(a) reduction with proprotein convertase subtilisin/kexin type 9 inhibitors: A systematic review and meta-analysis.J. Cardiovasc. Pharmacol.202177339740710.1097/FJC.000000000000096333298738
     [Google Scholar]
  29. SabatineM.S. GiuglianoR.P. KeechA.C. HonarpourN. WiviottS.D. MurphyS.A. KuderJ.F. WangH. LiuT. WassermanS.M. SeverP.S. PedersenT.R. Evolocumab and clinical outcomes in patients with cardiovascular disease.N. Engl. J. Med.2017376181713172210.1056/NEJMoa161566428304224
     [Google Scholar]
  30. WaldmannE. ParhoferK.G. Lipoprotein apheresis to treat elevated lipoprotein (a).J. Lipid Res.201657101751175710.1194/jlr.R05654926889050
     [Google Scholar]
  31. RoeselerE. JuliusU. HeiglF. SpitthoeverR. HeutlingD. BreitenbergerP. LeebmannJ. LehmacherW. KamstrupP.R. NordestgaardB.G. MaerzW. NoureenA. SchmidtK. KronenbergF. HeibgesA. KlingelR. SchettlerV. BenzingT. ChristH. WehnerS. Schulz-MerkelI. KuehnR. WagnerA. DschietzigW. ErnstC. KoziolekM. BuniaJ. KulzerP. KraenzleK-D. ToelleM. RiechersG. KuehnelC. MarsenT. SaehnC. RingelJ. MessnerH. OehringA. SchuerfeldC. WintergalenM. SchettlerV. NeumannF. KaulH. HaesnerM. PassfallJ. BenschneiderA. HeidenreichS. MärzW. KlaesR. BinnerP. DieplingerH. ErhartG. FassbenderC. ChristH. Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease.Arterioscler. Thromb. Vasc. Biol.20163692019202710.1161/ATVBAHA.116.30798327417585
     [Google Scholar]
  32. BorrelliM.J. YoussefA. BoffaM.B. KoschinskyM.L. New frontiers in lp(a)-targeted therapies.Trends Pharmacol. Sci.201940321222510.1016/j.tips.2019.01.00430732864
     [Google Scholar]
  33. TsimikasS. Karwatowska-ProkopczukE. XiaS. Lipoprotein(a) reduction in persons with cardiovascular disease.N. Engl. J. Med.202038221e6510.1056/NEJMc200486132433854
     [Google Scholar]
  34. WattsG. Work on RNA interference brings nobel triumph.BMJ20063337571717.110.1136/bmj.333.7571.71717023442
     [Google Scholar]
  35. KimY.K. RNA therapy: Rich history, various applications and unlimited future prospects.Exp. Mol. Med.202254445546510.1038/s12276‑022‑00757‑535440755
     [Google Scholar]
  36. TraberG.M. YuA.M. RNAi-based therapeutics and novel RNA bioengineering technologies.J. Pharmacol. Exp. Ther.2023384113315410.1124/jpet.122.00123435680378
     [Google Scholar]
  37. AdamsD. Gonzalez-DuarteA. O’RiordanW.D. YangC.C. UedaM. KristenA.V. TournevI. SchmidtH.H. CoelhoT. BerkJ.L. LinK.P. VitaG. AttarianS. Planté-BordeneuveV. MezeiM.M. CampistolJ.M. BuadesJ. BrannaganT.H.III KimB.J. OhJ. ParmanY. SekijimaY. HawkinsP.N. SolomonS.D. PolydefkisM. DyckP.J. GandhiP.J. GoyalS. ChenJ. StrahsA.L. NochurS.V. SweetserM.T. GargP.P. VaishnawA.K. GollobJ.A. SuhrO.B. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis.N. Engl. J. Med.20183791112110.1056/NEJMoa171615329972753
     [Google Scholar]
  38. BalwaniM. SardhE. VenturaP. PeiróP.A. ReesD.C. StölzelU. BissellD.M. BonkovskyH.L. WindygaJ. AndersonK.E. ParkerC. SilverS.M. KeelS.B. WangJ.D. SteinP.E. HarperP. VassiliouD. WangB. PhillipsJ. IvanovaA. LangendonkJ.G. KauppinenR. MinderE. HorieY. PenzC. ChenJ. LiuS. KoJ.J. SweetserM.T. GargP. VaishnawA. KimJ.B. SimonA.R. GouyaL. Phase 3 trial of rnai therapeutic givosiran for acute intermittent porphyria.N. Engl. J. Med.2020382242289230110.1056/NEJMoa191314732521132
     [Google Scholar]
  39. GarrelfsS.F. GansnerJ.M. LieskeJ.C. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1.N. Engl. J. Med.202138520e6910.1056/NEJMc210766134758265
     [Google Scholar]
  40. WattsJ.K. CoreyD.R. Silencing disease genes in the laboratory and the clinic.J. Pathol.2012226236537910.1002/path.299322069063
     [Google Scholar]
  41. WahaneA. WaghmodeA. KapphahnA. DhuriK. GuptaA. BahalR. Role of Lipid-based and polymer-based non-viral vectors in nucleic acid delivery for next-generation gene therapy.Molecules20202512286610.3390/molecules2512286632580326
     [Google Scholar]
  42. CheryJ. RNA therapeutics: RNAi and antisense mechanisms and clinical applications.Postdoc J.201647355010.14304/SURYA.JPR.V4N7.527570789
     [Google Scholar]
  43. BarresiV. MusmeciC. RinaldiA. CondorelliD.F. Transcript-targeted therapy based on rna interference and antisense oligonucleotides: Current applications and novel molecular targets.Int. J. Mol. Sci.20222316887510.3390/ijms2316887536012138
     [Google Scholar]
  44. O’DonoghueM.L. RosensonR.S. GencerB. LópezJ.A.G. LeporN.E. BaumS.J. StoutE. GaudetD. KnuselB. KuderJ.F. RanX. MurphyS.A. WangH. WuY. KassahunH. SabatineM.S. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease.N. Engl. J. Med.2022387201855186410.1056/NEJMoa221102336342163
     [Google Scholar]
  45. GaudetD. Karwatowska-ProkopczukE. BaumS.J. HurhE. KingsburyJ. BartlettV.J. FigueroaA.L. PiscitelliP. SingletonW. WitztumJ.L. GearyR.S. TsimikasS. O’DeaL.S.L. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia.Eur. Heart J.202041403936394510.1093/eurheartj/ehaa68932860031
     [Google Scholar]
  46. VarboA. FreibergJ.J. NordestgaardB.G. Remnant cholesterol and myocardial infarction in normal weight, overweight, and obese individuals from the copenhagen general population study.Clin. Chem.201864121923010.1373/clinchem.2017.27946329021326
     [Google Scholar]
  47. CrosbyJ. PelosoG.M. AuerPL. CrosslinDR TG and HDL working group of the exome sequencing project, national heart, lung, and blood institute; loss-of-function mutations in apoc3, triglycerides, and coronary disease.N Engl J Med.20143711223110.1056/NEJMoa130709524941081
     [Google Scholar]
  48. Karwatowska-ProkopczukE. TardifJ.C. GaudetD. BallantyneC.M. ShapiroM.D. MoriartyP.M. BaumS.J. AmourE.S. AlexanderV.J. XiaS. OtvosJ.D. WitztumJ.L. TsimikasS. Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia.J. Clin. Lipidol.202216561762510.1016/j.jacl.2022.06.00535902351
     [Google Scholar]
  49. KosmasC. Muñoz EstrellaA. SourlasA. SilverioD. HilarioE. MontanP. GuzmanE. Inclisiran: A new promising agent in the management of hypercholesterolemia.Diseases2018636310.3390/diseases603006330011788
     [Google Scholar]
  50. WongE. GoldbergT. Mipomersen (kynamro): A novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia.P&T201439211912224669178
     [Google Scholar]
  51. YeangC. Karwatowska-ProkopczukE. SuF. DinhB. XiaS. WitztumJ.L. TsimikasS. Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol.J. Am. Coll. Cardiol.202279111035104610.1016/j.jacc.2021.12.03235300814
     [Google Scholar]
  52. MalickW.A. GoonewardenaS.N. KoenigW. RosensonR.S. Clinical trial design for lipoprotein(a)-lowering therapies.J. Am. Coll. Cardiol.202381161633164510.1016/j.jacc.2023.02.03337076218
     [Google Scholar]
  53. TsamoulisD. SiountriI. RallidisL.S. Lipoprotein(a): Its association with calcific aortic valve stenosis, the emerging rna-related treatments and the hope for a new era in “treating” aortic valve calcification.J. Cardiovasc. Dev. Dis.20231039610.3390/jcdd1003009636975859
     [Google Scholar]
  54. AkoumianakisI. ZvintzouE. KypreosK. FilippatosT.D. ANGPTL3 and apolipoprotein c-iii as novel lipid-lowering targets.Curr. Atheroscler. Rep.20212352010.1007/s11883‑021‑00914‑733694000
     [Google Scholar]
  55. BergmarkB.A. MarstonN.A. BramsonC.R. CurtoM. RamosV. JevneA. KuderJ.F. ParkJ.G. MurphyS.A. VermaS. WojakowskiW. TerraS.G. SabatineM.S. WiviottS.D. CarbonneauD. Poulin-RobitailleR. WayneJ. LeeK. Mujica TrencheS. DzongowskiP. GaudetD. VanJ. AjaniD. BaysH. O’MahonyJ. JanasA. ScottJ. MoustafaM.A. RansomT. BenjaminS. AggarwalN. BogdanskiP. FriarsD. SchlosserR. OkopienB. BudhrajaM. FeldL. KlaffL. TellierG. MazzaG. WierzbickaI. Jazwinska-TarnawskaE. BoccalandroF. RosenstockJ. MarquezE. Barbel-JohnsonK. MadziarskaK. HeatonK. TardifJ-C. RubinoJ. TrevinoM. MoriartyK. GuptaA. WojakowskiW. FidelholtzJ. GuptaD. AlasaadH. ChristensenS. ShahP. LiS. ShermanM. FrechetteA. ArangoC. EganA. SrivastavaS. BajajA. InceC.Jr ZurakowskiA. Effect of vupanorsen on non–high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70.Circulation2022145181377138610.1161/CIRCULATIONAHA.122.05926635369705
     [Google Scholar]
  56. EsanO. WierzbickiA.S. Volanesorsen in the treatment of familial chylomicronemia syndrome or hypertriglyceridaemia: design, development and place in therapy.Drug Des. Devel. Ther.2020142623263610.2147/DDDT.S22477132753844
     [Google Scholar]
  57. WitztumJ.L. GaudetD. ArcaM. JonesA. SoranH. Gouni-BertholdI. StroesE.S.G. AlexanderV.J. JonesR. WattsL. XiaS. TsimikasS. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial.J. Clin. Lipidol.202317334235510.1016/j.jacl.2023.03.00737100699
     [Google Scholar]
  58. MarstonN.A. GiuglianoR.P. MelloniG.E.M. ParkJ.G. MorrillV. BlazingM.A. FerenceB. SteinE. StroesE.S. BraunwaldE. EllinorP.T. LubitzS.A. RuffC.T. SabatineM.S. Association of apolipoprotein b–containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis.JAMA Cardiol.20227325025610.1001/jamacardio.2021.508334773460
     [Google Scholar]
  59. GinsbergH.N. GoldbergI.J. Broadening the scope of dyslipidemia therapy by targeting apoc3 (apolipoprotein c3) and angptl3 (angiopoietin-like protein 3).Arterioscler. Thromb. Vasc. Biol.202343338839810.1161/ATVBAHA.122.31796636579649
     [Google Scholar]
  60. RayK.K. StoekenbroekR.M. KallendD. NishikidoT. LeiterL.A. LandmesserU. WrightR.S. WijngaardP.L.J. KasteleinJ.J.P. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels.JAMA Cardiol.20194111067107510.1001/jamacardio.2019.350231553410
     [Google Scholar]
  61. KettunenS. RuotsalainenA.K. Ylä-HerttualaS. RNA interference-based therapies for the control of atherosclerosis risk factors.Curr. Opin. Cardiol.202237436437110.1097/HCO.000000000000097235731681
     [Google Scholar]
  62. DesaiN.R. CampbellC. ElectricwalaB. PetrouM. TruemanD. WoodcockF. CristinoJ. Cost effectiveness of inclisiran in atherosclerotic cardiovascular patients with elevated low-density lipoprotein cholesterol despite statin use: a threshold analysis.Am. J. Cardiovasc. Drugs202222554555610.1007/s40256‑022‑00534‑935595929
     [Google Scholar]
  63. ScicchitanoP. MiloM. MallamaciR. De PaloM. CaldarolaP. MassariF. GabrielliD. ColivicchiF. CicconeM.M. Inclisiran in lipid management: A literature overview and future perspectives.Biomed. Pharmacother.202114311222710.1016/j.biopha.2021.11222734563953
     [Google Scholar]
  64. RayK.K. KallendD. LeiterL.A. RaalF.J. KoenigW. JarosM.J. SchwartzG.G. LandmesserU. Garcia CondeL. WrightR.S. ORION-11 Investigators Effect of inclisiran on lipids in primary prevention: the ORION-11 trial.Eur. Heart J.202243485047505710.1093/eurheartj/ehac61536331315
     [Google Scholar]
  65. JangA.Y. LimS. JoS.H. HanS.H. KohK.K. New trends in dyslipidemia treatment.Circ. J.202185675976810.1253/circj.CJ‑20‑103733177309
     [Google Scholar]
  66. O’DonoghueM.L. GiuglianoR.P. WiviottS.D. AtarD. KeechA. KuderJ.F. ImK. MurphyS.A. Flores-ArredondoJ.H. LópezJ.A.G. Elliott-DaveyM. WangB. MonsalvoM.L. AbbasiS. SabatineM.S. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease.Circulation2022146151109111910.1161/CIRCULATIONAHA.122.06162036031810
     [Google Scholar]
  67. BartoszewskiR. SikorskiA.F. Editorial focus: Understanding off-target effects as the key to successful RNAi therapy.Cell. Mol. Biol. Lett.20192416910.1186/s11658‑019‑0196‑331867046
     [Google Scholar]
  68. MengZ. LuM. RNA interference-induced innate immunity, off-target effect, or immune adjuvant?Front. Immunol.2017833110.3389/fimmu.2017.0033128386261
     [Google Scholar]
  69. WittrupA. LiebermanJ. Knocking down disease: A progress report on siRNA therapeutics.Nat. Rev. Genet.201516954355210.1038/nrg397826281785
     [Google Scholar]
  70. ZhuL. FangY. GaoB. JinX. ZhengJ. HeY. HuangJ. Correction: Effect of an increase in Lp(a) following statin therapy on cardiovascular prognosis in secondary prevention population of coronary artery disease.BMC Cardiovasc. Disord.202222157710.1186/s12872‑022‑03027‑436585611
     [Google Scholar]
/content/journals/cmp/10.2174/0118761429264553231204115314
Loading
RNA Interference-based Therapies for the Reduction of Cardiovascular Risk
Curr Mol Pharmacol 17, e18761429264553 (2024); https://doi.org/10.2174/0118761429264553231204115314
/content/journals/cmp/10.2174/0118761429264553231204115314
/content/journals/cmp/10.2174/0118761429264553231204115314
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): ASO; Cardiovascular risk reduction; LDL; Lipid lowering therapy; Lp(a); RNA interference; siRNA

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test